Remepy, a biotech pairing prescription medicines with therapeutic software, raised a $36 million Series A round, co-CEO Michal Tsur tells Axios exclusively.
Why it matters: Remepy is betting it can improve drug efficacy while helping drugmakers extend the commercial life of existing medicines.
